Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
VRTX

VRTX - Vertex Pharmaceuticals Inc Stock Price, Fair Value and News

426.78USD+7.15 (+1.70%)Market Closed
Watchlist

Market Summary

USD426.78+7.15
Market Closed
1.70%

VRTX Alerts

  • 8 major insider sales recently.

VRTX Stock Price

View Fullscreen

VRTX RSI Chart

VRTX Valuation

Market Cap

110.2B

Price/Earnings (Trailing)

30.46

Price/Sales (Trailing)

11.17

EV/EBITDA

22.12

Price/Free Cashflow

33.04

VRTX Price/Sales (Trailing)

VRTX Profitability

EBT Margin

44.38%

Return on Equity

20.59%

Return on Assets

15.92%

Free Cashflow Yield

3.03%

VRTX Fundamentals

VRTX Revenue

Revenue (TTM)

9.9B

Rev. Growth (Yr)

9.34%

Rev. Growth (Qtr)

1.38%

VRTX Earnings

Earnings (TTM)

3.6B

Earnings Growth (Yr)

18.31%

Earnings Growth (Qtr)

-6.42%

Breaking Down VRTX Revenue

Last 7 days

-0.2%

Last 30 days

-2.6%

Last 90 days

20.5%

Trailing 12 Months

42.0%

How does VRTX drawdown profile look like?

VRTX Financial Health

Current Ratio

3.99

VRTX Investor Care

Shares Dilution (1Y)

0.47%

Diluted EPS (TTM)

13.89

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20239.2B9.5B9.7B9.9B
20227.9B8.4B8.7B8.9B
20216.4B6.7B7.1B7.6B
20204.8B5.4B6.0B6.2B
20193.3B3.5B3.6B4.2B
20182.4B2.6B2.8B3.0B
20172.0B2.1B2.3B2.5B
20161.3B1.6B1.7B1.7B
2015600.5M628.1M759.0M1.0B
20141.0B829.7M787.0M580.4M
20131.4B1.3B1.2B1.2B
20121.8B2.1B1.8B1.5B
2011194.6M277.4M912.8M1.4B
2010100.3M112.9M111.7M143.4M
2009157.1M138.7M120.3M101.9M
2008000175.5M

Tracking the Latest Insider Buys and Sells of Vertex Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 20, 2024
wagner charles f jr
sold (taxes)
-1,182,670
420
-2,812
evp & chief financial officer
Feb 20, 2024
atkinson edward morrow iii
sold
-337,053
420
-801
evp, chief technical ops. off.
Feb 20, 2024
tatsis ourania
sold (taxes)
-1,418,620
420
-3,373
evp, chief reg. & quality off.
Feb 20, 2024
bozic carmen
sold (taxes)
-1,182,670
420
-2,812
evp and cmo
Feb 20, 2024
leiden jeffrey m
sold (taxes)
-1,731,950
420
-4,118
executive chairman
Feb 20, 2024
altshuler david
sold (taxes)
-1,182,670
420
-2,812
evp, global research and cso
Feb 20, 2024
atkinson edward morrow iii
sold (taxes)
-473,152
420
-1,125
evp, chief technical ops. off.
Feb 20, 2024
arbuckle stuart a
sold (taxes)
-1,418,620
420
-3,373
evp, coo
Feb 20, 2024
arbuckle stuart a
sold
-2,021,480
420
-4,804
evp, coo
Feb 20, 2024
sachdev amit
sold (taxes)
-1,103,180
420
-2,623
evp chief patient & ext af off

1–10 of 50

Which funds bought or sold VRTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 21, 2024
Raleigh Capital Management Inc.
added
150
13,399
20,407
0.01%
Feb 21, 2024
V-Square Quantitative Management LLC
added
103
563,406
971,653
0.17%
Feb 20, 2024
GLOBALT Investments LLC / GA
new
-
3,474,430
3,474,430
0.14%
Feb 20, 2024
VOISARD ASSET MANAGEMENT GROUP, INC.
new
-
110,268
110,268
0.07%
Feb 20, 2024
Able Wealth Management LLC
new
-
5,696
5,696
-%
Feb 20, 2024
READYSTATE ASSET MANAGEMENT LP
new
-
5,696
5,696
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-14.05
13,487,000
2,395,530,000
0.32%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
added
19.47
36,249
127,357
-%
Feb 16, 2024
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
added
34.98
43,396,600
118,289,000
0.15%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
added
1.36
8,916,130
56,842,100
0.23%

1–10 of 42

Are Funds Buying or Selling VRTX?

Are funds buying VRTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VRTX
No. of Funds

Unveiling Vertex Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.65%
22,281,729
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
capital world investors
8.6%
22,080,207
SC 13G/A
Jan 25, 2024
blackrock inc.
8.5%
21,881,203
SC 13G
Feb 13, 2023
capital world investors
5.0%
12,939,319
SC 13G
Feb 09, 2023
fmr llc
-
0
SC 13G
Feb 09, 2023
vanguard group inc
8.39%
21,546,903
SC 13G/A
Jan 24, 2023
blackrock inc.
9.4%
24,241,437
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
2.1%
5,421,291
SC 13G/A
Feb 10, 2022
vanguard group inc
7.93%
20,155,842
SC 13G/A

Recent SEC filings of Vertex Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 21, 2024
144
Notice of Insider Sale Intent
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading
Feb 21, 2024
4
Insider Trading

What is the Fair Value of VRTX?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Vertex Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Vertex Pharmaceuticals Inc News

Latest updates
InvestorPlace6 hours ago
Investor's Business Daily06 Feb 202408:00 am
The Motley Fool06 Jan 202408:00 am
FX Empire04 Jan 202408:00 am

Vertex Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue1.4%2,5182,4842,4932,3752,3032,3342,1962,0982,0731,9841,7931,7241,6281,5381,5241,5151,413950941858870
Costs and Expenses5.8%1,5291,4451,4671,5961,2691,2081,0901,0571,1959301,831837882866806795862850671582742
  S&GA Expenses39.9%369264263241267247215215255198195192212185192182195160157147153
  R&D Expenses--------6036944941,407456467493421449480556379339438
EBITDA Margin-0.2%0.46*0.46*0.46*0.46*0.48*0.47*0.48*0.37*0.37*0.40*0.37*0.52*---------
Interest Expenses100.0%--10.90-11.20-11.40-11.60-13.70-14.60-14.90-15.10-15.20-15.50-15.7016.00-13.86-13.87-14.1414.0015.0015.0015.0019.00
Income Taxes24.3%179144246192258246214193101231-11116828478.00-12.5055.0094.0013.0060.0052.00-1,492
Earnings Before Taxes-2.7%1,1481,1791,1628921,0771,1761,0249558711,083-44.2082188974682565867771.0032732032.00
EBT Margin-0.6%0.44*0.45*0.45*0.45*0.47*0.46*0.47*0.36*0.36*0.39*0.36*0.51*---------
Net Income-6.4%9691,03591670081993181176277085267.0065360466783760358358.002672691,551
Net Income Margin2.0%0.37*0.36*0.35*0.35*0.37*0.38*0.38*0.31*0.31*0.31*0.30*0.43*---------
Free Cashflow-85.6%1771,2281,0758581,0459011,087893933875-249850---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets4.6%22,73021,72620,34918,97418,15116,70615,58214,25613,43312,61912,22212,11511,75211,30210,2168,8938,3187,5157,0336,5436,262
  Current Assets-3.8%14,14414,69613,87312,96613,23512,27111,50410,3619,5618,8538,4588,5398,1337,4586,6945,4464,8234,7774,7114,1833,843
    Cash Equivalents-6.7%10,36911,11010,1519,29010,5049,1728,7027,6006,7956,2766,0646,3045,9885,3584,8313,5933,1093,3983,2952,8942,650
  Inventory7.3%739689604535461388368339353333322299281245219187168162143137124
  Net PPE--------------92172873674517.00731743812
  Goodwill0%1,0881,0881,0881,0881,08886.001,0021,0021,0001,0021,0021,0021,0001,0021,0021,0021,00044850.0050.0050.00
Liabilities-1.2%5,1505,2134,8794,5424,2383,6773,6493,3493,3333,0883,0253,1353,0653,1682,6972,4322,2332,2611,9641,8201,811
  Current Liabilities-1.4%3,5473,5993,3523,0262,7422,6092,5562,1802,1421,9141,8361,9441,8782,0041,7991,5391,3351,3891,2591,1061,120
Shareholder's Equity6.5%17,58016,51315,47014,43213,91313,03011,93410,90710,1009,5319,1968,9808,6878,1337,5196,4626,0855,2535,0704,7234,435
  Retained Earnings10.6%10,1429,1748,1387,2236,5235,7044,7733,9633,2012,4311,5791,512859254-412-1,250-1,852-2,436-2,493-2,761-3,029
  Additional Paid-In Capital1.5%7,4507,3407,3697,2207,3877,2267,1006,9306,8817,0867,6407,4997,8947,9177,9447,6967,9387,6687,5647,4767,421
Shares Outstanding-0.1%258258258258257256256255254258259259---------
Minority Interest----------------------
Float-------71,800---51,600---74,800---46,700--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-81.5%2351,2681,1349001,0789561,140956995927-1999214929081,039816446335464325315
  Share Based Compensation59.4%20913111912211213611413011910310511597.0010011711692.0085.0090.0094.0079.00
Cashflow From Investing-653.2%-886-117-303-1,833176-384-61.50-51.00-134-52.90-79.70-74.30244-24772.0032.00-896-249-50.19-39.14-40.90
Cashflow From Financing27.4%-119-16517.00-29440.00-60.2048.00-95.40-336-65634.00-518-125-140120-35916120.00-13.01-41.99-101
  Buy Backs20.2%14812326.00133----363642-425131108-30032.0012.0052.0094.00142

VRTX Income Statement

2023-12-31
Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Revenue$ 9,869.2$ 8,930.7$ 7,574.4
Costs and expenses:   
Cost of sales1,262.21,080.3904.2
Research and development expenses3,162.92,540.31,937.8
Acquired in-process research and development expenses527.1115.51,113.3
Selling, general and administrative expenses1,136.6944.7840.1
Change in fair value of contingent consideration(51.6)(57.5)(3.1)
Total costs and expenses6,037.24,623.34,792.3
Income from operations3,832.04,307.42,782.1
Interest income614.7144.64.9
Interest expense(44.1)(54.8)(61.5)
Other (expense) income, net(22.8)(164.8)4.9
Income before provision for income taxes4,379.84,232.42,730.4
Provision for income taxes760.2910.4388.3
Net income$ 3,619.6$ 3,322.0$ 2,342.1
Net income per common share:   
Basic (in dollars per share)$ 14.05$ 12.97$ 9.09
Diluted (in dollars per share)$ 13.89$ 12.82$ 9.01
Shares used in per share calculations:   
Basic (in shares)257.7256.1257.7
Diluted (in shares)260.5259.1259.9
Product revenues, net   
Revenues:   
Revenue$ 9,869.2$ 8,930.7$ 7,573.4
Other revenues   
Revenues:   
Revenue$ 0.0$ 0.0$ 1.0

VRTX Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 10,369.1$ 10,504.0
Marketable securities849.2274.5
Accounts receivable, net1,563.41,442.2
Inventories738.8460.6
Prepaid expenses and other current assets623.7553.5
Total current assets14,144.213,234.8
Property and equipment, net1,159.31,108.4
Goodwill1,088.01,088.0
Other intangible assets, net839.9603.6
Deferred tax assets1,812.11,246.9
Operating lease assets293.6347.4
Long-term marketable securities2,497.8112.2
Other assets895.3409.6
Total assets22,730.218,150.9
Current liabilities:  
Accounts payable364.9303.9
Accrued expenses2,655.32,126.7
Other current liabilities527.2311.5
Total current liabilities3,547.42,742.1
Long-term finance lease liabilities376.1430.8
Long-term operating lease liabilities348.6379.5
Other long-term liabilities877.7685.8
Total liabilities5,149.84,238.2
Commitments and contingencies0.00.0
Shareholders’ equity:  
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding0.00.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 257,695,221 and 257,011,628 shares issued and outstanding, respectively2.62.6
Additional paid-in capital7,449.77,386.5
Accumulated other comprehensive (loss) income(14.3)0.8
Retained earnings10,142.46,522.8
Total shareholders’ equity17,580.413,912.7
Total liabilities and shareholders’ equity$ 22,730.2$ 18,150.9
VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEwww.vrtx.com
 EMPLOYEES4800

Vertex Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Vertex Pharmaceuticals Inc? What does VRTX stand for in stocks?

VRTX is the stock ticker symbol of Vertex Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vertex Pharmaceuticals Inc (VRTX)?

As of Thu Feb 22 2024, market cap of Vertex Pharmaceuticals Inc is 110.24 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VRTX stock?

You can check VRTX's fair value in chart for subscribers.

What is the fair value of VRTX stock?

You can check VRTX's fair value in chart for subscribers. The fair value of Vertex Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vertex Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vertex Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether VRTX is over valued or under valued. Whether Vertex Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Vertex Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VRTX.

What is Vertex Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, VRTX's PE ratio (Price to Earnings) is 30.46 and Price to Sales (PS) ratio is 11.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vertex Pharmaceuticals Inc's stock?

In the past 10 years, Vertex Pharmaceuticals Inc has provided 0.179 (multiply by 100 for percentage) rate of return.